Krystal Biotech stock had its Relative Strength (RS) Rating upgraded from 88 to 93 Thursday.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. This proprietary rating tracks technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the last 52 weeks matches up against the rest of the market.
Over 100 years of market history shows that the best-performing stocks tend to have an RS Rating of over 80 in the early stages of their moves.
See How IBD Helps You Make More Money In Stocks
Is Krystal Biotech Stock A Buy?
Krystal Biotech stock is now considered extended and out of buy range after clearing a 52.50 buy point in a first-stage cup without handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The biotech firm showed -79% earnings growth in its most recent report, while sales growth came in at 0%. The next quarterly results are expected on or around May 10.
Krystal Biotech stock holds the No. 107 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharmaceutcls, Pacira Pharmaceuticals and Regeneron Pharmaceutical are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
